Intra-Cellular Therapies (NASDAQ:ITCI) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI) in a research report report published on Wednesday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Several other analysts have also commented on the company. Piper Sandler reiterated a “neutral” rating and set a $132.00 price objective (up previously from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Mizuho lowered Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and reduced their target price for the stock from $140.00 to $132.00 in a research note on Monday, February 24th. Royal Bank of Canada restated a “sector perform” rating and issued a $132.00 target price (up previously from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Cantor Fitzgerald upgraded Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 14th. Finally, Baird R W lowered Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Ten research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $106.08.

Intra-Cellular Therapies Trading Up 0.0 %

Shares of NASDAQ ITCI opened at $131.25 on Wednesday. The stock has a market capitalization of $13.96 billion, a PE ratio of -150.86 and a beta of 0.69. The stock’s fifty day simple moving average is $122.06 and its two-hundred day simple moving average is $94.74. Intra-Cellular Therapies has a 12-month low of $63.30 and a 12-month high of $131.37.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The business had revenue of $199.22 million for the quarter, compared to analysts’ expectations of $205.08 million. On average, equities analysts predict that Intra-Cellular Therapies will post -0.64 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Intra-Cellular Therapies

A number of institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its position in shares of Intra-Cellular Therapies by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 9,721,360 shares of the biopharmaceutical company’s stock valued at $811,928,000 after acquiring an additional 93,107 shares during the period. Wasatch Advisors LP grew its position in shares of Intra-Cellular Therapies by 3.5% during the 3rd quarter. Wasatch Advisors LP now owns 3,848,588 shares of the biopharmaceutical company’s stock valued at $281,601,000 after acquiring an additional 130,351 shares during the period. Norges Bank acquired a new stake in shares of Intra-Cellular Therapies during the 4th quarter valued at about $268,347,000. Invesco Ltd. grew its position in shares of Intra-Cellular Therapies by 2.9% during the 4th quarter. Invesco Ltd. now owns 3,077,174 shares of the biopharmaceutical company’s stock valued at $257,006,000 after acquiring an additional 87,582 shares during the period. Finally, Bellevue Group AG grew its position in shares of Intra-Cellular Therapies by 0.6% during the 3rd quarter. Bellevue Group AG now owns 2,485,627 shares of the biopharmaceutical company’s stock valued at $181,873,000 after acquiring an additional 14,342 shares during the period. 92.33% of the stock is currently owned by institutional investors and hedge funds.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.